Although there is prolonged PFS and OS of Osimertinib over the earlier EGFR-TKIs, and a reduction in AE like elevated aminotransferase or rash, its prominent fatigue has become a tough nuisance exacerbating QoL concerns in patients with advanced NSCLC [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.